{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T08:48:40Z","timestamp":1795250920816,"version":"4.10.3"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,27]],"date-time":"2027-03-27T00:00:00Z","timestamp":1806105600000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["R01 AI150917"],"award-info":[{"award-number":["R01 AI150917"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["T32 AI007526"],"award-info":[{"award-number":["T32 AI007526"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015213","name":"The University of Texas Medical Branch at Galveston Sealy Institute for Vaccine Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015213","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007865","name":"University of Texas Medical Branch","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128526","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:12:17Z","timestamp":1774599137000},"page":"128526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evaluation of Rift Valley fever vaccine candidates in pregnant rodent models"],"prefix":"10.1016","volume":"80","author":[{"given":"Cigdem","family":"Alkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Jurado-Cobena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128526_bb0005","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-ento-010715-023819","article-title":"Rift Valley fever: an emerging mosquito-borne disease","volume":"61","author":"Linthicum","year":"2016","journal-title":"Annu Rev Entomol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of Rift Valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128526_bb0015","doi-asserted-by":"crossref","unstructured":"Kuhn JH, Brown K, Adkins S, de la Torre JC, Digiaro M, Ergunay K, et al. Promotion of order Bunyavirales to class Bunyaviricetes to accommodate a rapidly increasing number of related polyploviricotine viruses. J Virol 2024;98:e0106924. doi:https:\/\/doi.org\/10.1128\/jvi.01069-24.","DOI":"10.1128\/jvi.01069-24"},{"key":"10.1016\/j.vaccine.2026.128526_bb0020","unstructured":"CDC. Possession, use, and transfer of select agents and toxins; biennial review of the list of select agents and toxins and enhanced biosafety requirements. Final rule. Fed Regist 2017;82:6278\u201394."},{"key":"10.1016\/j.vaccine.2026.128526_bb0025","doi-asserted-by":"crossref","unstructured":"Walper SA, Lasarte Aragones G, Sapsford KE, Brown CW, 3rd, Rowland CE, Breger JC, et al. Detecting biothreat agents: from current diagnostics to developing sensor technologies. ACS Sens 2018;3:1894\u20132024. doi:https:\/\/doi.org\/10.1021\/acssensors.8b00420.","DOI":"10.1021\/acssensors.8b00420"},{"key":"10.1016\/j.vaccine.2026.128526_bb0030","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1093\/infdis\/jiad267","article-title":"Viral prototypes for pandemic preparedness: the road ahead","volume":"228","author":"Morabito","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128526_bb0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.20506\/rst.39.1.3082","article-title":"The world organisation for animal health: notification of animal diseases","volume":"39","author":"Caceres","year":"2020","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.vaccine.2026.128526_bb0040","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/vaccines11030707","article-title":"Perspectives of next-generation live-attenuated Rift Valley fever vaccines for animal and human use","volume":"11","author":"Wichgers Schreur","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128526_bb0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41541-023-00769-w","article-title":"Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates","volume":"8","author":"Alkan","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128526_bb0050","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine phase 2 clinical trial: safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128526_bb0055","doi-asserted-by":"crossref","unstructured":"Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA, Gibbs PH, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 1999;18:181\u20139. doi:https:\/\/doi.org\/10.1016\/s0264-410x(99)00213-3.","DOI":"10.1016\/S0264-410X(99)00218-2"},{"key":"10.1016\/j.vaccine.2026.128526_bb0060","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","article-title":"Candidate vaccines for human Rift Valley fever","volume":"19","author":"Ikegami","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2026.128526_bb0065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"Ikegami","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128526_bb0070","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0075","unstructured":"Hills RE. Issuance of a conditional license for Rift Valley fever vaccine, modified live virus. Notice no. 13\u201312. Center for Veterinary Biologics, Ames, IA. 2013."},{"key":"10.1016\/j.vaccine.2026.128526_bb0080","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/CVI.00114-15","article-title":"Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated Rift Valley fever virus vaccine candidate, in sheep","volume":"22","author":"Miller","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0085","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L segments","volume":"89","author":"Ikegami","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0090","doi-asserted-by":"crossref","unstructured":"McMillen CM, Megli C, Radisic R, Skvarca LB, Hoehl RM, Boyles DA, et al. Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface. J Virol 2024;98:e0098324. doi:https:\/\/doi.org\/10.1128\/jvi.00983-24.","DOI":"10.1128\/jvi.00983-24"},{"key":"10.1016\/j.vaccine.2026.128526_bb0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128526_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2020.100070","article-title":"Safety and immunogenicity of the Rift Valley fever arMP-12 $\\Delta$NSm21\/384 candidate vaccine in pregnant ewes","volume":"6","author":"Boumart","year":"2020","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.128526_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004550","article-title":"Rift Valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths","volume":"10","author":"Makoschey","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128526_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00536-3","article-title":"Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models","volume":"7","author":"Ikegami","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128526_bb0115","doi-asserted-by":"crossref","unstructured":"McMillen CM, Arora N, Boyles DA, Albe JR, Kujawa MR, Bonadio JF, et al. Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection. Sci Adv 2018;4:eaau9812. doi:https:\/\/doi.org\/10.1126\/sciadv.aau9812.","DOI":"10.1126\/sciadv.aau9812"},{"key":"10.1016\/j.vaccine.2026.128526_bb0120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41541-025-01230-w","article-title":"Maternal vaccination with live-attenuated Rift Valley fever virus protects offspring via immune transfer","volume":"10","author":"Hertel","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128526_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02004-20","article-title":"Development of a simian RNA polymerase I promoter-driven reverse genetics for the Rescue of Recombinant Rift Valley Fever Virus from Vero cells","volume":"95","author":"Ikegami","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0130","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1128\/JVI.00476-06","article-title":"NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture","volume":"80","author":"Won","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0135","doi-asserted-by":"crossref","unstructured":"McMillen CM, Boyles DA, Kostadinov SG, Hoehl RM, Schwarz MM, Albe JR, et al. Congenital Rift Valley fever in Sprague Dawley rats is associated with diffuse infection and pathology of the placenta. PLoS Negl Trop Dis 2022;16:e0010898. doi:https:\/\/doi.org\/10.1371\/journal.pntd.0010898.","DOI":"10.1371\/journal.pntd.0010898"},{"key":"10.1016\/j.vaccine.2026.128526_bb0140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2016.05.008","article-title":"Zika virus infection during pregnancy in mice causes placental damage and Fetal demise","volume":"165","author":"Miner","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128526_bb0145","doi-asserted-by":"crossref","unstructured":"Bohm EK, Vangorder-Braid JT, Jaeger AS, Moriarty RV, Baczenas JJ, Bennett NC, et al. Zika virus infection of pregnant Ifnar1(\u2212\/\u2212) mice triggers strain-specific differences in fetal outcomes. J Virol 2021;95:e0081821. doi:https:\/\/doi.org\/10.1128\/JVI.00818-21.","DOI":"10.1128\/JVI.00818-21"},{"key":"10.1016\/j.vaccine.2026.128526_bb0150","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1099\/vir.0.051250-0","article-title":"Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice","volume":"94","author":"Indran","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128526_bb0160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vetmic.2014.04.007","article-title":"Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination","volume":"172","author":"Wilson","year":"2014","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/humupd\/dmg043","article-title":"A comparison of placental development and endocrine functions between the human and mouse model","volume":"9","author":"Malassine","year":"2003","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.vaccine.2026.128526_bb0170","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.4049\/jimmunol.180.4.2029","article-title":"Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells","volume":"180","author":"Hughes","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0175","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/978-1-0716-3926-9_27","article-title":"Laboratory animal models for Rift Valley fever virus disease","volume":"2824","author":"Freeman","year":"2024","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2026.128526_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007898","article-title":"Rift Valley fever virus targets the maternal-foetal interface in ovine and human placentas","volume":"14","author":"Oymans","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128526_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/s44298-024-00017-5","article-title":"Organoids in virology","volume":"2","author":"Chu","year":"2024","journal-title":"NPJ Viruses"},{"key":"10.1016\/j.vaccine.2026.128526_bb0190","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41586-018-0753-3","article-title":"Trophoblast organoids as a model for maternal-fetal interactions during human placentation","volume":"564","author":"Turco","year":"2018","journal-title":"Nature"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:37Z","timestamp":1792515757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"alternative-id":["S0264410X26003348"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128526","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Rift Valley fever vaccine candidates in pregnant rodent models","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128526"}}